Monitoring of hormonal therapy in patients with metastatic breast carcinoma by plasma marker protein profiles.
Approximately 50% of the present patients with metastatic breast carcinoma, who were treated with hormonal therapy, had increased plasma levels of CEA or GCDFP. With therapy, serially decreasing plasma levels of these marker proteins appeared an accurate indicator of a favorable response, whereas increasing levels indicated disease progression.
D001053:Apolipoproteins; D053399:Apolipoproteins D; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000628:therapy*; D002352:Carrier Proteins; D005260:Female; D006023:Glycoproteins; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D026901:Membrane Transport Proteins; D009363:Neoplasm Proteins / Q000097:blood*
C024328:APOD protein, human; D001053:Apolipoproteins; D053399:Apolipoproteins D; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D002352:Carrier Proteins; D006023:Glycoproteins; D006728:Hormones; D026901:Membrane Transport Proteins; D009363:Neoplasm Proteins